This study is a prospective, multicenter, single-arm clinical trial conducted in China to evaluate the efficacy and safety of a novel left ventricular assist device, SynFlow Duro system, manufactured by ForQaly Medical in the treatment of post cardiotomy cardiogenic shock.
18≤Age≤80, any sex.
Failure to wean from CPB or refractory cardiogenic shock after cardiac surgery.
Body surface area>2.5m2.
Presence of any cardiac assist device (other than an IABP).
Right ventricular failure.
Evidence of any vascular disease or anatomy precluding placement or deployment of the device (e.g. severely calcified vessel).